BR0116763A - Human Specific Antibodies for Selective Cancer Therapy - Google Patents
Human Specific Antibodies for Selective Cancer TherapyInfo
- Publication number
- BR0116763A BR0116763A BR0116763-4A BR0116763A BR0116763A BR 0116763 A BR0116763 A BR 0116763A BR 0116763 A BR0116763 A BR 0116763A BR 0116763 A BR0116763 A BR 0116763A
- Authority
- BR
- Brazil
- Prior art keywords
- construct
- specifically
- target
- binding
- cancer therapy
- Prior art date
Links
- 238000011275 oncology therapy Methods 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 238000002823 phage display Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
"ANTICORPOS HUMANOS ESPECìFICOS PARA TERAPIA SELETIVA DO CNCER". A presente invenção refere-se a um peptídeo ou polipeptídeo consistindo de uma molécula Fv, uma construção da mesma, um fragmento da referida molécula ou da referida construção, ou uma construção de um fragmento tendo características de ligação acentuadas, de modo a ligar-se seletivamente e/ou especificamente a uma célula alvo em favor de outras células, em que a seletividade ou especificidade da ligação é primordialmente determinada por uma primeira região hipervariável e em que o Fv é um scFv ou um dsfv, e tendo, opcionalmente, um ou mais tags. A ligação acentuada refere-se a um sítio de ligação substancialmente exposto e/ou superexpresso sobre um alvo, ou em um alvo, que compreende uma célula em favor de outras células sobre as quais, ou nas quais, o sítio de ligação não é substancialmente disponível e/ou expresso. A invenção refere-se ainda a um método para isolar os referidos peptídeos e polipeptídeos de uma biblioteca de exibição de fagos e às moléculas de ácido nucléico que as codificam. A invenção provê uma composição farmacêutica que compreende o peptídeo ou polipeptídeo e kits para diagnóstico e tratamento de doença, especificamente câncer, mais especificamente leucemia mielóide aguda."SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY". The present invention relates to a peptide or polypeptide consisting of an Fv molecule, a construct thereof, a fragment of said molecule or said construct, or a fragment construct having enhanced binding characteristics, so as to bind selectively and/or specifically to a target cell in favor of other cells, wherein the selectivity or specificity of binding is primarily determined by a first hypervariable region, and wherein the Fv is an scFv or a dsfv, and optionally having one or more more tags. Enhanced binding refers to a substantially exposed and/or overexpressed binding site on a target, or in a target, comprising a cell in favor of other cells on which, or in which, the binding site is not substantially available and/or express. The invention further relates to a method for isolating said peptides and polypeptides from a phage display library and the nucleic acid molecules encoding them. The invention provides a pharmaceutical composition comprising the peptide or polypeptide and kits for diagnosing and treating disease, specifically cancer, more specifically acute myelogenous leukemia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75118100A | 2000-12-29 | 2000-12-29 | |
| PCT/US2001/049440 WO2002059264A2 (en) | 2000-12-29 | 2001-12-31 | Specific human antibodies for selective cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0116763A true BR0116763A (en) | 2004-03-09 |
Family
ID=25020844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0116763-4A BR0116763A (en) | 2000-12-29 | 2001-12-31 | Human Specific Antibodies for Selective Cancer Therapy |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1353937A4 (en) |
| JP (1) | JP2004524023A (en) |
| KR (1) | KR20030091952A (en) |
| CN (1) | CN100374456C (en) |
| AU (1) | AU2002246737B2 (en) |
| BR (1) | BR0116763A (en) |
| CA (1) | CA2433227A1 (en) |
| CZ (1) | CZ20031983A3 (en) |
| HU (1) | HUP0400775A2 (en) |
| IL (1) | IL156690A0 (en) |
| MX (1) | MXPA03005944A (en) |
| NZ (1) | NZ527173A (en) |
| PL (1) | PL365758A1 (en) |
| RU (1) | RU2316564C2 (en) |
| WO (1) | WO2002059264A2 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005534679A (en) * | 2002-07-01 | 2005-11-17 | サビエント ファーマシューティカルズ，インコーポレイティド | Compositions and methods for therapeutic treatment |
| EP1646401A4 (en) * | 2003-06-30 | 2007-07-18 | Bio Technology General Israel | SPECIFIC HUMAN ANTIBODIES |
| BRPI0608096A2 (en) | 2005-04-26 | 2009-11-10 | Pfizer | p-cadherin antibodies |
| EP2373343B1 (en) * | 2008-12-19 | 2015-02-11 | Philogen S.p.A. | Immunocytokines for tumour therapy with chemotherapeutic agents |
| EP2590993B1 (en) * | 2010-07-09 | 2015-05-06 | Affibody AB | Polypeptides |
| CN101948534B (en) * | 2010-08-19 | 2014-05-28 | 中国科学院生物物理研究所 | Method for screening antibodies |
| GB201310544D0 (en) * | 2013-06-13 | 2013-07-31 | Ucb Pharma Sa | Obtaining an improved therapeutic ligand |
| US9695234B2 (en) * | 2014-10-23 | 2017-07-04 | Singh Molecular Medicine, Llc | Single domain antibodies directed against STAT3 |
| CA2970255A1 (en) * | 2014-12-17 | 2016-06-23 | Intrexon Corporation | Intercalated single-chain variable fragments |
| GB201506868D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
| US12509530B2 (en) | 2015-08-27 | 2025-12-30 | Singh Moelcular Medicine, LLC | Single domain antibodies directed against intracellular antigens |
| CN108290940B (en) * | 2015-10-01 | 2021-12-07 | 圣拉斐尔医院有限公司 | TCR and uses thereof |
| DK3377103T4 (en) * | 2015-11-19 | 2025-05-19 | Revitope Ltd | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| CN117603353A (en) * | 2016-09-14 | 2024-02-27 | 特尼奥生物股份有限公司 | CD3 binding antibodies |
| WO2018119215A1 (en) | 2016-12-21 | 2018-06-28 | Teneobio, Inc. | Anti-bcma heavy chain-only antibodies |
| JP7164544B2 (en) * | 2017-04-11 | 2022-11-01 | インヒブルクス インコーポレイテッド | Multispecific polypeptide constructs with restricted CD3 binding and methods of using same |
| CN112218686A (en) | 2018-04-11 | 2021-01-12 | 印希比股份有限公司 | Multispecific polypeptide constructs with restricted CD3 binding and related methods and uses |
| CA3140029A1 (en) | 2019-05-14 | 2020-11-19 | Prometheus Biosciences, Inc. | Tl1a patient selection methods, systems, and devices |
| BR112023009172A2 (en) * | 2020-11-13 | 2023-10-03 | Cedars Sinai Medical Center | METHODS, SYSTEMS AND KITS FOR TREATMENT OF INFLAMMATORY DISEASES TAILORED TO TL1A |
| CN116333100A (en) * | 2022-10-31 | 2023-06-27 | 南京欧凯生物科技有限公司 | A rapid purification method of recombinant human IgM antibody |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6140470A (en) * | 1995-06-30 | 2000-10-31 | Yale University | Human monoclonal anti-tumor antibodies |
| PT988056E (en) * | 1997-01-22 | 2003-09-30 | Univ Texas | METHODS AND COMPOSITIONS OF A TUMOR FACTOR FOR THE TREATMENT OF COAGULATION AND TUMORS |
-
2001
- 2001-12-31 JP JP2002559551A patent/JP2004524023A/en active Pending
- 2001-12-31 CN CNB018228852A patent/CN100374456C/en not_active Expired - Fee Related
- 2001-12-31 IL IL15669001A patent/IL156690A0/en unknown
- 2001-12-31 CA CA002433227A patent/CA2433227A1/en not_active Abandoned
- 2001-12-31 MX MXPA03005944A patent/MXPA03005944A/en not_active Application Discontinuation
- 2001-12-31 CZ CZ20031983A patent/CZ20031983A3/en unknown
- 2001-12-31 KR KR10-2003-7008885A patent/KR20030091952A/en not_active Ceased
- 2001-12-31 AU AU2002246737A patent/AU2002246737B2/en not_active Ceased
- 2001-12-31 RU RU2003123100/13A patent/RU2316564C2/en not_active IP Right Cessation
- 2001-12-31 BR BR0116763-4A patent/BR0116763A/en not_active IP Right Cessation
- 2001-12-31 EP EP01994329A patent/EP1353937A4/en not_active Withdrawn
- 2001-12-31 HU HU0400775A patent/HUP0400775A2/en unknown
- 2001-12-31 NZ NZ527173A patent/NZ527173A/en unknown
- 2001-12-31 WO PCT/US2001/049440 patent/WO2002059264A2/en not_active Ceased
- 2001-12-31 PL PL01365758A patent/PL365758A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA03005944A (en) | 2005-04-29 |
| EP1353937A4 (en) | 2005-04-13 |
| WO2002059264A3 (en) | 2003-03-06 |
| AU2002246737B2 (en) | 2007-03-01 |
| CN100374456C (en) | 2008-03-12 |
| RU2316564C2 (en) | 2008-02-10 |
| CN1551886A (en) | 2004-12-01 |
| IL156690A0 (en) | 2004-01-04 |
| CZ20031983A3 (en) | 2005-07-13 |
| PL365758A1 (en) | 2005-01-10 |
| RU2003123100A (en) | 2005-03-10 |
| JP2004524023A (en) | 2004-08-12 |
| HUP0400775A2 (en) | 2007-05-02 |
| NZ527173A (en) | 2006-03-31 |
| CA2433227A1 (en) | 2002-08-01 |
| WO2002059264A2 (en) | 2002-08-01 |
| KR20030091952A (en) | 2003-12-03 |
| EP1353937A2 (en) | 2003-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0116763A (en) | Human Specific Antibodies for Selective Cancer Therapy | |
| BRPI0819909B8 (en) | isolated human or humanized synthetic antibody or a functional fragment thereof, functional fragment and pharmaceutical composition | |
| BRPI0618399A2 (en) | isolated antigen binding region that is specific for cd38, isolated antibody or a functional fragment thereof that is specific for cd38, isolated antibody or a functional fragment thereof, isolated immunoglobulin, heavy chain variable of an isolated antigen binding region, variable light chain from an isolated antigen binding region, isolated nucleic acid sequence, nucleic acid sequence encoding a variable heavy chain from an isolated antigen binding region, nucleic acid sequence, vector, isolated cell, pharmaceutical composition, use of the pharmaceutical composition, method of inducing specific death of cd38-expressing tumor cells, method of detecting specific death of cd38-expressing tumor cells, method of detecting the presence of cd38 in a minipore source tissue or cell , cd38 detection method in a cd3-expressing erythrocyte 8 and diagnostic composition | |
| BRPI0418766A (en) | antibodies and molecules derived from these that bind to steap-1 proteins | |
| CY1118462T1 (en) | Monoclonal Antibody Against Osteoprotein Protein Connection | |
| BRPI0607486A2 (en) | humanized l243 antibody, bispecific antibody or antigen binding fragments thereof, pharmaceutical composition, kit and use of said antibodies | |
| BRPI0607315A2 (en) | isolated polynucleotide, expression vector, composition, method of producing an antigen binding molecule, antigen binding molecule and the use thereof, method for detecting in vivo or in vitro the presence of egfr in a sample, engineered host cell , pharmaceutical composition and its use | |
| BR0307837A (en) | Anti-spruce antibodies and their use | |
| BRPI0808940A8 (en) | human antibody or binding fragment thereof, antigen, polynucleotide, vector, host cell, method for preparing an antibody or immunoglobulin binding fragment or chain (s) thereof, antibody, immunoglobulin chain or binding fragment thereof , composition, uses of the antibody or binding fragment, an antigen, a polynucleotide, a vector, or a cell, and a tumor antigen binding molecule, method for molecular cloning of an antibody, and kit for the diagnosis of a tumor | |
| BRPI0816117B8 (en) | isolated monoclonal antibody or fragment thereof, pharmaceutical composition, kit for treating cholesterol-related disorders, and use of an antigen-binding protein or a monoclonal antibody or fragment thereof | |
| BRPI0417429A (en) | isolated monoclonal antibody or an antigen binding portion thereof, composition, immunoconjugate, bispecific molecule, expression vector, host cell, transgenic mouse, hybridoma, and methods of inhibiting an inflammatory or autoimmune response, treating an inflammatory or autoimmune disease, treating a viral or bacterial infection and preparing an anti-ip-10 antibody | |
| AR012035A1 (en) | METHOD FOR DETECTING PROSTATE CANCER, METHOD FOR MONITORING DEVELOPMENT OF PROSTATE CANCER, MONOCLONAL ANTIBODY THAT JOINS A POLYPEPTIDE, AN EFFECTIVE THERAPEUTIC AMOUNT OF MONOCLONAL ANTIBODIES TO PREPARE MEDICINES AND EQUIPMENT FOR | |
| BR112018015238A2 (en) | antibody conjugate, antibody, kit, pharmaceutical composition, and methods for treating or preventing a disease or condition and for diagnosing a disease or condition | |
| BRPI0607757A2 (en) | antibody, composition, immunoconjugate, bispecific molecule, isolated nucleic acid molecule, expression vector, host cell, hybridoma, method for preparing an anti-psma antibody, and, uses of an antibody, or antigen binding portion thereof | |
| HRP20170879T1 (en) | Differential in tumour gene products and use of same | |
| BRPI0606790A2 (en) | isolated human antibody or antigen binding portion thereof, isolated polypeptide, composition, isolated nucleic acid, host cell expression vector, rabies vaccine, kit, use of an isolated human monoclonal antibody or antigen binding portion thereof, or an effective amount of a composition, a method for identifying an antibody or fragment thereof, antibody or fragment thereof, antibody or fragment thereof, and glycoprotein. | |
| ATE421537T1 (en) | RECOGNITION MOLECULES FOR THE TREATMENT AND DETECTION OF TUMORS | |
| BR112021009275A2 (en) | Humanized anti-sirp alpha antibody or an antigen-binding fragment thereof, pharmaceutical composition, nucleic acid molecule, and host cell. | |
| CN105277712B (en) | A kind of method for identifying the modification of lysine ε amino side chains monomethylation | |
| BR112022012474A2 (en) | ANTI-LILRB1 ANTIBODY, ANTIGEN BINDING FRAGMENT THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING THEM, USE OF SUCH ANTIBODY TO TREAT OR PREVENT CANCER, METHOD OF PREPARING SUCH ANTIBODY, NUCLEIC ACID MOLECULE AND RECOMBINANT CELL AND VECTOR. | |
| BR112012013915A8 (en) | anti-c4 antibodies. 4a and uses thereof | |
| BR9808863A (en) | Peptide antiestrogenic compositions and methods to treat breast cancer | |
| Lu-Culligan et al. | Acetyl-methyllysine marks chromatin at active transcription start sites | |
| BRPI0414446A (en) | methods for screening for a therapeutic agent, for suppressing the polynucleotide sequence, for treating a non-steroidal cancer, for screening for binding of an agent specifically to a polynucleotide, and for determining whether a patient is at risk for developing or having a non-steroidal cancer, pharmaceutical composition, uses of a therapeutic agent, an antisense molecule or a cell that expresses and / or contains the antisense molecule, at least one of the immunogenic membrane proteins, fragments, derivatives or homologues thereof or from a cell containing and / or expressing at least one of the immunogenic membrane proteins or fragments, derivatives or homologues thereof and an agent or antibody, agent, and kit for identifying a patient at risk of developing or have non-steroidal cancer | |
| ES2098274T3 (en) | MONOCLONAL ANTIBODIES. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: SAVIENT PHARMACEUTICALS, INC. (US) Free format text: ALTERADO DE: BIO-TECHNOLOGY GENERAL CORPORATION |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A E 10A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2125 DE 27/09/2011. |